MRC Agrotech Ltd has successfully completed the allotment of 1,08,40,007 equity shares on preferential basis following its Board of Directors meeting held on January 3, 2026. The company allotted shares at ₹19.50 per equity share with a face value of ₹10.00 each to both promoter and non-promoter categories, as announced in its regulatory filing to BSE.

Share Allotment Breakdown

The board meeting, which commenced at 11:45 AM and concluded at 12:15 PM, resulted in the successful allotment of shares across two distinct consideration categories:

Cash Consideration Allottees

The company allotted 21,97,910 equity shares for cash consideration to eight non-promoter investors. The major allottees include Tejal Pratyush Bhartiya (4,50,000 shares), Swati Jain (4,50,000 shares), Santosh Dube (4,09,200 shares), and Vikram Bajaj HUF (3,50,000 shares). Other investors include Sillenium Infra Project Pvt Ltd, Devjeet Chakraborty, Saurabh Goswami, and Neetu Singh.

Non-Cash Consideration and Strategic Acquisition

The larger portion of 86,42,097 shares was allotted for consideration other than cash, primarily for acquiring 100% equity shares of MARSAPI Life Sciences Private Limited on a share swap basis. The allottees include both promoter and non-promoter categories:

Regulatory Compliance and Background

The allotment was executed pursuant to BSE's in-principle approval granted vide letter no. LOD/PREF/TT/FIP/1400/2025-26 dated December 22, 2025. The preferential issue was previously approved by shareholders during an Extraordinary General Meeting held on June 28, 2025. The allotment complies with Chapter V of SEBI ICDR Regulations and Regulation 30 of SEBI LODR Regulations.

Post-Allotment Shareholding Impact

Following the allotment, significant changes occurred in the shareholding pattern. Wordexx Ventures Pvt Ltd emerged as a major shareholder with 10.62% stake, while Ashok Kumar Singh holds 6.94% and Vindu Mahendra Pratap Singh holds 5.14%. The allotment strengthens the company's capital base while facilitating the strategic acquisition of MARSAPI Life Sciences Private Limited.

Company Secretary Rahul Mathur signed the disclosure documents dated January 3, 2026, ensuring full compliance with stock exchange notification requirements and regulatory obligations.

MRC Agrotech Ltd has filed an application with BSE Limited seeking in-principle approval for a preferential issue of equity shares under Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has applied to issue 21.97 lakh equity shares for cash and 86.42 lakh shares for non-cash consideration on a preferential basis.

Preferential Issue Structure

The company proposes to issue equity shares in two tranches through preferential allotment. The issue comprises both cash and non-cash components, with specific allocations for different investor categories.

The issue price of ₹19.50 per share includes a face value of ₹10.00 and a premium of ₹9.50 per share. This pricing is determined based on the floor price calculated according to Chapter V of the SEBI ICDR Regulations.

Revised Fund Utilization Plan

The company issued a disclosure under Regulation 30 on December 19, 2025, significantly revising the utilization of preferential issue proceeds. The Board of Directors decided that no part of the preferential issue proceeds will be utilized towards repayment or pre-payment of borrowings, as all outstanding short-term obligations were repaid from internal accruals prior to June 2025.

Working Capital Deployment Strategy

The incremental working capital requirement of ₹313.30 lakhs is based on CMA workings prepared using the last 3 years audited financials. The deployment is planned between January 2026 and March 2026.

Future Funding Requirements

An additional ₹100.00 lakhs has been earmarked for future funding requirements, specifically focusing on R&D facility setup, product launches, and expansion into nutraceuticals.

R&D Facility Development

The company plans to establish a pilot R&D facility at Belapur, Thane, with an estimated cost of ₹30.00 lakhs. The facility will focus on bio-formulation development and include specialized equipment for fermentation, sterilization, analytical testing, and processing.

Product Launch Activities

The company has allocated ₹20.00 lakhs for product launch activities, focusing on two proprietary formulations from the MARSAPI IP portfolio.

Nutraceuticals and Soil Health Expansion

The company has earmarked ₹25.00 lakhs for initial expansion into nutraceuticals and soil health management products, covering the feasibility and development phase.

Non-Cash Component - Acquisition Strategy

The non-cash component of 86,42,097 shares, aggregating to ₹16,85,20,896, is intended for the acquisition of 100% shareholding in MARSAPI Lifesciences Private Limited. This share swap arrangement involves issuing company shares to the existing shareholders of the target company as consideration for their equity stakes.

Authorized Capital Enhancement

To accommodate the preferential issue, the company proposes to increase its authorized share capital from ₹20,50,00,000 to ₹35,50,00,000, divided into 3.55 crore equity shares of ₹10 each. This increase requires amendments to the Memorandum and Articles of Association.

Regulatory Compliance

The preferential issue is subject to various regulatory approvals and compliance requirements. The company has obtained valuation reports from registered valuers and ensured compliance with SEBI ICDR Regulations. The equity shares proposed for allotment will be subject to lock-in periods as specified under Chapter V of the SEBI ICDR Regulations.

The allotment is expected to be completed within 15 days from the date of passing the special resolution by members, subject to receipt of necessary regulatory approvals. The company has undertaken to maintain transparency in disclosures and ensure utilization of proceeds strictly in line with applicable SEBI ICDR Regulations.